• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,328.19 -516.33
( -0.66%)
Global Indices
Nasdaq
49,619.91 1.93
(0.00%)
Dow Jones
7,417.79 59.68
(0.81%)
Hang Seng
62,681.30 -152.54
(-0.24%)
Nikkei 225
10,228.01 -48.94
(-0.48%)
Forex
USD-INR
94.38 -0.30
(-0.31%)
EUR-INR
110.93 -0.26
(-0.23%)
GBP-INR
128.32 -0.39
(-0.30%)
JPY-INR
0.60 0.00
(-0.28%)

EQUITY - MARKET SCREENER

Vaibhav Global Ltd
Industry :  Diamond Cutting / Jewellery
BSE Code
ISIN Demat
Book Value()
532156
INE884A01027
43.8889359
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
VAIBHAVGBL
26.78
3919.41
EPS(TTM)
Face Value()
Div & Yield %
8.76
2
0.64
 

antariksh industries ltd
Dr Reddy's Lab gets EIR from USFDA for Srikakulam facility
Mar 06,2026
The USFDA classified the inspection outcome as “Voluntary Action Indicated” (VAI) and confirmed that the inspection has been officially closed under 21 CFR 20.64(d)(3).

The inspection included both a Good Manufacturing Practice (GMP) review and a Pre-Approval Inspection (PAI) conducted at the company’s FTO-SEZ PU01 facility. The company had earlier informed about the USFDA inspection on 12 December 2025.

Hyderabad-based Dr Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

Dr Reddy’s Laboratories reported a 14.4% decline in consolidated net profit to Rs 1,209.8 crore despite a 4.4% jump in revenue to Rs 8,716.8 crore in Q3 FY26 over Q3 FY25.

The counter shed 0.91% to Rs 1,301.10 on the BSE.